Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL

To elucidate dynamic changes in native BCR‐ABL and alternatively spliced tyrosine kinase inhibitor (TKI)‐resistant but function‐dead BCR‐ABL(Ins35bp) variant, following commencement or discontinuation of TKI therapy, each transcript was serially quantified in patients with chronic myeloid leukemia (...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Yuda, Junichiro, Odawara, Jun, Minami, Mariko, Muta, Tsuyoshi, Kohno, Kentaro, Tanimoto, Kazuki, Eto, Tetsuya, Shima, Takahiro, Kikushige, Yoshikane, Kato, Koji, Takenaka, Katsuto, Iwasaki, Hiromi, Minami, Yosuke, Ohkawa, Yasuyuki, Akashi, Koichi, Miyamoto, Toshihiro
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7385367/
https://ncbi.nlm.nih.gov/pubmed/32314454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14424
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars